This Experimental Hematology & Oncology series on 'New developments in CAR T, CAR NK, and CAR macrophage cell therapies' is open. CAR engineered cell therapies are moving rapidly from bench to bedside. This collection welcomes studies covering the latest development in pre-clinical and clinical studies of CAR -engineered cell therapies. Submissions can be made via the journal's submission system. For more information, visit the full collection webpage.
Call for papers: New developments in CAR T, CAR NK, and CAR macrophage cell therapies
Call for papers: Latest updates from major conferences
This Experimental Hematology & Oncology and Journal of Hematology & Oncology series intends to publish Correspondences with latest updates on novel agents and regimens from major conferences on blood and cancer disorders. Each Correspondence serves as a summary and analysis of 5 or more abstracts on a similar focus from a major international conference. Submissions can be made via the journal's submission system. For more information, visit the full collection page.
Featured Article: The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives
In a new review, Caracciolo et al. look over new developments, challenges and perspectives of the emerging landscape of immunotherapy of T-cell malignancies.
Articles
-
-
Ubiquitin modification in the regulation of tumor immunotherapy resistance mechanisms and potential therapeutic targets
-
Polyunsaturated fatty acids promote M2-like TAM deposition via dampening RhoA-YAP1 signaling in the ovarian cancer microenvironment
-
Genetic factors, risk prediction and AI application of thrombotic diseases
-
Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China
-
Breast cancer brain metastases: the last frontier
-
COVID-19 vaccination associated severe immune thrombocytopenia
-
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
-
Leukemia incidence trends at the global, regional, and national level between 1990 and 2017
-
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
Colorectal Cancer Awareness Month
In recognition of Colorectal Cancer Awareness Month this March, we have selected a collection of articles on colorectal cancer from across our open access portfolio. Together, these articles contribute to the evolving landscape of colorectal cancer research and the fight against this prevalent and impactful disease.
Aims and scope
Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings.
Editors-in-Chief
Delong Liu, New York Medical College
Kongming Wu, Tongji Medical College
Editor's quote (Dr. Delong Liu)
"Like our companion journal, Journal of Hematology & Oncology, Experimental Hematology & Oncology publishes on all aspects of hematology and oncology, which are closely intertwined and rapidly evolving fields. It also emphasizes basic and translational research, as well as patient-oriented research and clinical trials with ‘negative’ or preliminary results. The journal is an international platform for sharing findings in these areas and adheres to fast turnaround times."
Follow
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 9.4
5-year Journal Impact Factor: 8.3
Source Normalized Impact per Paper (SNIP): 1.583
SCImago Journal Rank (SJR): 2.384Speed 2023
Submission to first editorial decision (median days): 2
Submission to acceptance (median days): 100Usage 2023
Downloads: 696,150
Altmetric mentions: 375
On the blog
-
-
Winners of the 2022 Cardio-Oncology Journal Prize
06 April 2023
-
